<p>Whole-body fat mass (g) and semi-fasted blood lipid levels of obese hyperlipidemic hamsters treated for 27 days with vehicle (PO, QD), liraglutide (0.2 mg/kg, SC, BID) or linagliptin (3.0 mg/kg, PO, QD). Values are means ± SEM (n = 6 per group; P<0.05 (*); P<0.01 (**); P<0.001 (***) vs. vehicle group).</p><p>Effect of liraglutide and linagliptin on body weight, and blood lipids.</p
<p>Values are given as mean ± SEM. *<i>P</i><0.05; **<i>P</i><0.01; ***<i>P</i><0.001 compared with ...
<p>(<b>a</b>) Schematic representation of the study. (<b>b</b>) Body weight. There is no difference ...
Liraglutide, a glucagon-like peptide-1 analog, has been proved to reduce body weight and visceral ad...
<p>(A) Body weight change (% of day 0) of obese hyperlipidemic hamsters treated for 26 days with veh...
<p>(A) Body weight change (% of day 0), (B) Cumulative total energy intake (kJ), (C) cumulative inta...
<p>Semi-fasted blood lipid levels of obese hyperlipidemic hamsters treated for 14 days with vehicle ...
<p>C57BL/6 mice were fed a high-fat diet (HFD) for either 2 months and treated with linagliptin (3 m...
Social isolation contributes to the development of obesity and insulin-independent diabetes in KKAy ...
<p>(A) body weights during liraglutide treatment (n = 6–7). Open circles, liraglutide-treated <i>Gcg...
The incretin effect is essential for glucose homeostasis. Glucagon-like peptide 1 (GLP-1) based drug...
<p>The body weight (A) and random fed state blood glucose levels (B) were monitored weekly in vehicl...
<p>C57BL/6 mice were fed a high-fat diet (HFD) or chow diet for 3 months followed by treatment with ...
Linagliptin (TRADJENTA™) is a selective dipeptidyl peptidase-4 (DPP-4) inhibitor. DPP-4 inhibition a...
Linagliptin (TRADJENTATM) is a selective dipeptidyl peptidase-4 (DPP-4) inhibitor. DPP-4 inhibition ...
Ellen E Ladenheim Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School...
<p>Values are given as mean ± SEM. *<i>P</i><0.05; **<i>P</i><0.01; ***<i>P</i><0.001 compared with ...
<p>(<b>a</b>) Schematic representation of the study. (<b>b</b>) Body weight. There is no difference ...
Liraglutide, a glucagon-like peptide-1 analog, has been proved to reduce body weight and visceral ad...
<p>(A) Body weight change (% of day 0) of obese hyperlipidemic hamsters treated for 26 days with veh...
<p>(A) Body weight change (% of day 0), (B) Cumulative total energy intake (kJ), (C) cumulative inta...
<p>Semi-fasted blood lipid levels of obese hyperlipidemic hamsters treated for 14 days with vehicle ...
<p>C57BL/6 mice were fed a high-fat diet (HFD) for either 2 months and treated with linagliptin (3 m...
Social isolation contributes to the development of obesity and insulin-independent diabetes in KKAy ...
<p>(A) body weights during liraglutide treatment (n = 6–7). Open circles, liraglutide-treated <i>Gcg...
The incretin effect is essential for glucose homeostasis. Glucagon-like peptide 1 (GLP-1) based drug...
<p>The body weight (A) and random fed state blood glucose levels (B) were monitored weekly in vehicl...
<p>C57BL/6 mice were fed a high-fat diet (HFD) or chow diet for 3 months followed by treatment with ...
Linagliptin (TRADJENTA™) is a selective dipeptidyl peptidase-4 (DPP-4) inhibitor. DPP-4 inhibition a...
Linagliptin (TRADJENTATM) is a selective dipeptidyl peptidase-4 (DPP-4) inhibitor. DPP-4 inhibition ...
Ellen E Ladenheim Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School...
<p>Values are given as mean ± SEM. *<i>P</i><0.05; **<i>P</i><0.01; ***<i>P</i><0.001 compared with ...
<p>(<b>a</b>) Schematic representation of the study. (<b>b</b>) Body weight. There is no difference ...
Liraglutide, a glucagon-like peptide-1 analog, has been proved to reduce body weight and visceral ad...